药品监管事务：开放获取

局部晚期乳腺癌患者大剂量表柔比星新辅助化疗不同周期成本效益分析：4 Fe 100 c Vs. 6 Fe 100 C

Abstract

Ramirez-Torres Nicolas MC?Herrera-Abarca Jorge Eduardo DC?Chavez-Carbajal Jose Fortino MC ? Hernandez Valencia Marcelino DC

????????????NCT???????????????LABC??????????????????????????????????

???????NCT????????

?????????III???????????????4FE100C vs.6FE100C?????????CEA??????48????

?????? ???????pCR??

??????????????????????? (ICER)?????????????????????? 2005 ??????? (MXN) ($) ?????????????????? (SSP???????? IMSS) ??????????? 3 ? 4 ?????????????????? 3% ???????????????????

???? 4FE100C ????? 6FE100C ????????? 6FE100C ? 4E100C ? NCT ????????????????? 30,467.00 ??????2,343.61 ???? 18,004.00 ??????1,384.92 ?????????????? CEA ???6 FE100C ????? (C/E) ?????????? (ICER) ?????? 11,765,925.42 ????? (905,071.20 ??)????????????????? (pCR) ???????????? 6 FE100C ?? 4 FE100C???????????????????

??? 6FE100C????????????????????LABC???????